Journal
MOLECULAR THERAPY-ONCOLYTICS
Volume 24, Issue -, Pages 160-170Publisher
CELL PRESS
DOI: 10.1016/j.omto.2021.12.010
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81702482, 82073232, 81700769, 81641028, 81602297]
- Biomedical Research Foundation
- Hubei University of Medicine [HBMUPI201803]
- Hubei Science & Technology Department Foundation [2020CFB558, 2018ACA162]
- Key projects of Hubei Education [D20202103]
- Key Projects of Precision Medicine [2016JZ01]
Ask authors/readers for more resources
This study compared the effects of two different transfection reagents on gene transfer, and tested a therapeutic application model using synthetic modified tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mRNA. The research demonstrated that synthetic mRNA can be successfully delivered into the brain using commercially available transfection reagents, with TransIT-mRNA showing better results than in vivo-jetPEI kit. This model can be used for precise targeting and personalized gene therapy of glioma.
Owing to messenger RNA's unique biological advantages, it has received increasing attention to be used as a therapeutic, known as mRNA-based gene therapy. It is critical to have an ideal strategy of mRNA gene therapy for glioma, which grows in a special environment. In the present study, we screened out a safe and efficient transfection reagent for intracranial delivery of synthetic mRNA in mouse brain. First, in order to analyze the effect of different transfection reagents on the intracranial delivery of mRNA, the synthetic luciferase mRNA was wrapped with two different transfection reagents and microinjected into the brain at the fixed point. The expression status of delivered mRNA was monitored by a small animal imaging system. The possible reagent-induced biological toxicity was evaluated by behavioral and blood biochemical measurements. Then, to test the therapeutic effect of our intracranial delivery mRNA model on glioma, synthetic modified tumor necrosis factor-related apoptosisinducing ligand (TRAIL) mRNA was used as an example of therapeutic application. This model demonstrated that synthetic mRNA could be successfully delivered into the brain using commercially available transfection reagents, and TransIT-mRNA showed better results than in vivo-jetPEI kit. This model can be applied in precise targeting and personalized gene therapy of glioma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available